Renewable Energy Group and Phillips 66 Pulled the Plug on Partnership. What's Next?
A long-awaited and very important joint venture has been sidelined indefinitely. It could hurt investors in the long run.
Here's Why Lithium Stocks Were Soaring Today
Investors are coming around to the idea that global demand for lithium-ion batteries is about to pick up.
Is Sol-Gel Technologies a Buy?
The under-the-radar pharma company might have one of the industry's more promising approaches to dermatology treatments.
Here's Why Amyris Shares Rose as Much as 12.5% Today
Another year, another set of financing transactions that provide a lifeline to the struggling company.
Is Apellis Pharmaceuticals a Buy?
The pre-commercial company is looking to take on a $23 billion industry leader. Promising late-stage clinical results suggest it may have a shot.
Here's Why These Small-Cap Pharma Stocks Are Volatile Today
Two stocks fell, while one popped, as investors speculate over the potential financial impact from the Wuhan coronavirus outbreak. (Hint: it's unlikely to move the needle.)
Codexis Is Chasing a Blockbuster Opportunity. Can It Compete With Gene Therapies?
The company is developing a novel enzyme-based treatment for phenylketonuria (PKU), but it faces growing competition from potentially curative gene therapies.
Coronavirus Uncertainty Spreads, but Investors Should Remain Calm
If you wouldn't invest in flu vaccines, then you shouldn't view the ongoing coronavirus outbreak as a noteworthy investing opportunity.
Here's Why Adaptive Biotechnologies Is Soaring Today
The genetic diagnostics company announced the pricing of a common stock offering that suggests there's solid demand for shares.
2 Top Biotech Stocks to Buy Right Now
These two companies are pushing the envelope of immunotherapies by developing unique cell types. Each has promising results for investors to consider.
Here's Why Moderna Stock Rose as Much as 10.8% Today
The company is working on a vaccine to protect against the latest coronavirus spreading from China, but investors are getting a little ahead of themselves.
Here's Why Arrowhead Pharmaceuticals Lost as Much as 14.2% Today
The biopharma stock received an analyst downgrade.
These Gene-Editing Pioneers Are Making Bold Bets in Agriculture
Investors shouldn't forget that the world of biotech extends beyond biopharmaceuticals.
Here's Why Coeur Mining Stock Fell as Much as 17.5% Today
The precious-metals miner reported preliminary results for the fourth quarter of 2019.
2 Stocks to Buy and Hold for Decades
These companies aren't household names, but they quietly enable customers across the pharmaceutical and biopharmaceutical sectors to bring innovative new products to market.
2 Top Dividend Stocks to Buy in January
These two businesses generate comfortable levels of cash flow, return some of that to investors, and have healthy growth opportunities ahead.
Here's Why Rigel Pharmaceuticals Is Erupting This Week
The pharmaceutical stock is surging after providing preliminary results for the fourth quarter of 2019.
2 Top Renewable Energy Stocks to Buy Right Now
These two renewable energy stocks offer investors a way to own a piece of the ongoing energy transition, which will accelerate in the 2020s.
Here's Why Clovis Oncology Rose as Much as 25.6% Today
Investors might be getting a little carried away with news from the FDA.
2 Top Growth Stocks to Buy in January
Two pharma stocks, one riding a wave of enthusiasm and one getting unfairly punished, look appealing from a long-term standpoint.